How do biosimilars sustain value, affordability, and access to oncology care?

Simoens, Steven

doi:10.1080/14737167.2020.1813570

Cited by 11 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few studies have explored cost differences between IV biosimilar trastuzumab and SC reference trastuzumab [ 26 ]. More research is required that replicates our cost estimates in healthcare systems that are organized and financed differently than in Belgium and that takes into account market dynamics and shifts in prescribing practices between different trastuzumab formulations.…”

Section: Discussionmentioning

confidence: 99%

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study

Simoens

Vulto

Dylst³

2021

Pharmaceuticals

Self Cite

View full text Add to dashboard Cite

This study aimed to compare drug costs and healthcare costs of a 1 year adjuvant course with intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in HER2-positive breast cancer from the Belgian hospital perspective. Our simulation is based on the methodology used by Tjalma and colleagues, and considered costs of drugs, healthcare professional time and consumables. We calculated intravenous drug costs for different body weights, and computed drug costs and healthcare costs to treat 100 patients with either trastuzumab formulation, assuming a binomial body weight distribution in this sample. Scenarios were run to account for drug discounts and intravenous vial sharing. Drug costs amounted to €1,431,282 with intravenous biosimilar trastuzumab and €1,522,809 with subcutaneous reference trastuzumab for a sample of 100 patients in the base case analysis. When healthcare professional time and consumables were also considered, healthcare costs with intravenous biosimilar trastuzumab were similar to those with subcutaneous reference trastuzumab. Differences in healthcare costs between intravenous biosimilar trastuzumab and subcutaneous reference trastuzumab depended on the level of discounts on these formulations and on intravenous vial sharing. Our case study demonstrates that comparing costs of intravenous vs. subcutaneous formulations is complex and multifactorial, and entails more than a simple cost comparison of products.

show abstract

Section: Discussionmentioning

confidence: 99%

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study

Simoens

Vulto

Dylst³

2021

Pharmaceuticals

Self Cite

View full text Add to dashboard Cite

show abstract

“…Biosimilars can enhance value, affordability, and patient access to oncology care, thereby inducing a shift within the broader market dynamics. 64 In the broader perspective, the transition towards utilising lower cost biosimilars can result in a notable reduction in the total cost of care, whilst maintaining the quality of care for those living with cancer. Article…”

Section: Articlementioning

confidence: 99%

Real-World Evidence of Biosimilar Utilisation and Pharmacoeconomics in People Living with Breast or Lung Cancer

Moir

2023

EMJ Oncol

View full text Add to dashboard Cite

As the medical community continues to explore and harness the potential of biosimilars, it is imperative to accumulate robust real-world evidence (RWE) to guide informed decision-making, and enhance patient outcomes in cancer treatment. This article reviews the current understanding and utilisation of biosimilars in the treatment of breast and lung cancers by reviewing existing RWE. A literature search of PubMed, MEDLINE, and Scopus was performed to analyse observational studies pertaining to the adoption of biosimilars in people living with breast or lung cancer, with publications considered since 2019. The review summarises the current RWE relating to biosimilar use for its approved indications across breast and lung cancer. Despite the scarcity of evidence addressing the cost-effectiveness of biosimilars in breast and lung cancer treatment, biosimilars may offer a dual benefit by enhancing patient outcomes, while ensuring cost-effectiveness, thereby increasing access to oncology therapies globally. The increased access to biosimilars within community oncology practices, hospitals, and national healthcare systems, promises substantial cost savings. This review highlights the evolving landscape of biosimilar utilisation in oncology, revealing their potential as a more affordable and inclusive approach to cancer care, while also indicating areas for further research.

show abstract

“…However, these investigations have failed to apprehend all the cost inferences of intravenous against subcutaneous reference products for example, loss of productivity which is associated with giving the drug at home or in hospital, costs associated with transport, utilization in therapy regimen inclusive of intravenous chemotherapy, and nursing time costs. 44 Also, according to a physician's survey which was conducted in United States and in emerging markets, almost half of the oncologists gave a report that they were interested to increase the usage of HER2 mAb treatment in entire treatment settings only if biosimilar of trastuzumab in lesser cost is available. 45 The healthcare systems which are centralized and those which have a strong history of use of generic medicine, utilization of biosimilar will distinctly increase with forecast of more than 80% of prescribing for some of the biologics in less than 1 year of entry into market in United States.…”

Section: Overview Of Economic Impact and Financial Savings From Biosimilar Utilizationmentioning

confidence: 99%

Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies

Safdar

Butt

Ahmad

et al. 2021

J Oncol Pharm Pract

View full text Add to dashboard Cite

Stupendous elevation in the healthcare costs has followed with the inception of the current unconventional options of treatment available for cancer patients. There is a dire need of innovative financing approaches to lessen the financial load on healthcare system. Biosimilars are biological drugs consisting of an active ingredient from a reference biological drug that has a great potential of relieving financial load. Strict requirements from regulatory point of view are required as biosimilars are exceedingly similar to but not identical to the reference product. This provides with a certainty that no consequential differences from clinical point of view as compared to the respective biologics exists with regards to efficacy, safety and purity. Safety and effectiveness of biosimilars have been disclosed since more than 10 years of affirmations. However, there is a need to educate the healthcare professionals to abolish potential misconceptions and coalesce biosimilars into regular clinical practice. The present review focuses on providing an overview of regulatory aspects and requirements for biosimilars, the main challenges in the selection and development of biosimilars and the economic impact and financial savings observed in recent studies carried out in different parts of the world. In addition, we have discussed the different successful comparative studies which have been done in different parts of the world to depict the biosimilarity for monoclonal antibodies such as bevacizumab, trastuzumab and rituximab.

show abstract

How do biosimilars sustain value, affordability, and access to oncology care?

Cited by 11 publications

References 14 publications

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study

Real-World Evidence of Biosimilar Utilisation and Pharmacoeconomics in People Living with Breast or Lung Cancer

Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies

Contact Info

Product

Resources

About